Patents Assigned to Hanmi Pharm. Co., Ltd.
  • Protein complex by use of a specific site of an immunoglobulin fragment for linkage
    Patent number: 11207383
    Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 28, 2021
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Dae Jin Kim, Jong Soo Lee, Young Jin Park, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
  • Combination of cross-linked hyaluronic acids and method of preparing the same
    Patent number: 11180576
    Abstract: Provided are a combination of cross-linked hyaluronic acids comprising: a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, and a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, and a method for preparing the same.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: November 23, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Chul Choi, Hyun Il Kim, Ki Young Yang, Hyo Seung Park, Back Ho Lee
  • THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME
    Publication number: 20210338779
    Abstract: Provided are a combination including glucagon and a compound or substance with therapeutic activity against a metabolic syndrome and a use thereof.
    Type: Application
    Filed: October 4, 2019
    Publication date: November 4, 2021
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Jung Kuk KIM, Young Jin PARK, In Young CHOI, Sang Don LEE, Jong Suk LEE
  • ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING THE SAME
    Publication number: 20210330666
    Abstract: An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent. A method of preparing an oral solid formulation includes forming granules containing irinotecan or a pharmaceutically acceptable salt thereof, a diluent, and a binder, mixing the granules with a disintegrant and a lubricant to obtain a mixture, and includes adding an acidifying agent in step of forming granules and/or mixing the granules.
    Type: Application
    Filed: July 8, 2021
    Publication date: October 28, 2021
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Caleb Hyung Min PARK, Myeong Ki JUNG, Jin Cheul KIM, Yong Il KIM, Jae Hyun PARK, Jong Soo WOO
  • A PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION WITH IMPROVED CONTENT UNIFORMITY COMPRISING SUSTAINED-RELEASE PELLETS CONTAINING TAMSULOSIN HYDROCHLORIDE
    Publication number: 20210322319
    Abstract: Provided is an oral pharmaceutical formulation including sustained-release pellets containing tamsulosin hydrochloride and a pharmaceutically acceptable additive, wherein the sustained-release pellets includes about 50 wt % to about 100 wt % of particles having a particle size of about 0.50 mm to about 0.85 mm, and less than about 15 wt % of particles having a particle size less than about 0.50 mm. The oral pharmaceutical formulation may have a reduced deviation in dissolution rate of tamsulosin hydrochloride and improved content uniformity among unit dosage forms, and have ensured quality due to high reproducibility of unit dosage forms.
    Type: Application
    Filed: July 14, 2017
    Publication date: October 21, 2021
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Hyung Seo KIM, Jung Hyun CHO, Jin Cheul KIM, Yong II KIM, Jae Hyun PARK, Jong Soo WOO
  • IgG4 Fc fragment comprising modified hinge region
    Patent number: 11147857
    Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: October 19, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
  • Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
    Patent number: 11142559
    Abstract: The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: October 12, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Glucagon derivatives with improved stability
    Patent number: 11135271
    Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: October 5, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Jong Min Lee, Sang Yun Kim, Sung Min Bae, Sung Youb Jung, Se Chang Kwon
  • Antibody specifically binding to PD-1 and functional fragment thereof
    Patent number: 11117967
    Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 14, 2021
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Yaping Yang, Jiawang Liu, Nanmeng Song, Hongjuan Zhang, Mengxie Jin
  • Oral solid formulation containing irinotecan and method of preparing the same
    Patent number: 11090299
    Abstract: An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: August 17, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Caleb Hyung Min Park, Myeong Ki Jung, Jin Cheul Kim, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody
    Patent number: 11072651
    Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 27, 2021
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Nanmeng Song, Jiawang Liu, Yaping Yang, Yang Yang, Dongge Yang, Hongjuan Zhang, Mengxie Jin
  • Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region
    Patent number: 11071785
    Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 27, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
  • Esomeprazole-containing complex capsule and preparation method therefor
    Patent number: 11052048
    Abstract: Provided are a composite capsule and a method of preparing the composite capsule. The composite capsule includes a first dissolving part including a core, an inner coating layer on the core, and a first enteric coating layer on the inner coating layer, wherein core contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof. The composite capsule further includes a second dissolving part including a core, which contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof, an inner coating layer on the core, and a second enteric coating layer on the inner coating layer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: July 6, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Taek Kwan Kwon, Seung Hun Chang, Ho Taek Im, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
    Publication number: 20210188937
    Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 24, 2021
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Jong Suk LEE, Young Jin PARK, Chang Ki LIM, Sung Youb JUNG, Se Chang KWON
  • Crystalline forms of hydrochloride salts of thienopyrimidine compound
    Patent number: 11008333
    Abstract: A crystalline form of an alkyl benzene sulfonyl urea compound that is useful as an oral antidiabetics is disclosed. Specifically, the compound is a hydrochloride salt of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide of the following formula I.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: May 18, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jong Ouk Baek, Ji Young Jeon, Hee Sook Oh, Hee Cheol Kim, Sun Young Jang, Tae Hee Ha
  • FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE IMMUNOGLOBULIN CONJUGATE
    Publication number: 20210138070
    Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.
    Type: Application
    Filed: December 28, 2020
    Publication date: May 13, 2021
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Hwa Peoung RIM, Hyun Uk KIM, Ho Taek IM, Sang Yun KIM, Hyung Kyu LIM, Sung Min BAE, Se Chang KWON
  • Liquid formulation of long-acting human growth hormone immunoglobulin conjugate
    Patent number: 10987425
    Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 27, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hwa Peoung Rim, Hyun Uk Kim, Ho Taek Im, Sang Yun Kim, Hyung Kyu Lim, Sung Min Bae, Se Chang Kwon
  • Liquid formulation of long-acting insulin conjugate
    Patent number: 10987424
    Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: April 27, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Min Young Kim, Sung Min Bae, Se Chang Kwon
  • Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 10981967
    Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 20, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • IgG4 Fc fragment comprising modified hinge region
    Patent number: 10973881
    Abstract: The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: April 13, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi